<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547612</url>
  </required_header>
  <id_info>
    <org_study_id>070222</org_study_id>
    <secondary_id>07-C-0222</secondary_id>
    <secondary_id>CDR0000570181</secondary_id>
    <nct_id>NCT00547612</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer</brief_title>
  <official_title>Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using&#xD;
      [18F]-labeled substance P antagonist receptor quantifier, may be effective in finding disease&#xD;
      in patients with pancreatic cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying how well a PET scan using [18F]-labeled substance P&#xD;
      antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether [18F]-labeled substance P antagonist receptor quantifier positron&#xD;
           emission tomography can identify pancreatic cancer evident on multiphase CT scan.&#xD;
&#xD;
      OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than&#xD;
      15 days later, patients receive [18F]-labeled substance P antagonist receptor quantifier IV&#xD;
      and undergo positron emission tomography over 6 hours.&#xD;
&#xD;
      Blood is collected periodically to measure the metabolism of the radiotracer by high&#xD;
      performance liquid chromatography with radioactive detectors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography</measure>
  </primary_outcome>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[18F]-labeled substance P antagonist receptor quantifier</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Primary or metastatic disease&#xD;
&#xD;
          -  At least one site of measurable disease&#xD;
&#xD;
          -  Enrolled in an NCI protocol (either a treatment or screening protocol) such as&#xD;
             NCI-05-C-0044 or NCI-05-C-0141&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  WBC ≥ 1,200/mm³&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must agree to use effective contraception&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Allergy to IV contrast&#xD;
&#xD;
          -  Claustrophobia that would preclude completion of a scan or unable to lie on one's back&#xD;
             for positron emission tomography scan&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  More than 4 weeks since prior abdominal surgery&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior participation in other research protocols within the past year such that a&#xD;
             radiation exposure together with the present study would exceed the annual limits&#xD;
&#xD;
          -  Aprepitant within 72 hours of [18F]-labeled substance P antagonist receptor quantifier&#xD;
             positron emission tomography&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E. Royal, MD, FACS</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>October 19, 2007</study_first_submitted>
  <study_first_submitted_qc>October 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2007</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance P</mesh_term>
    <mesh_term>Neurokinin A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

